Beam Therapeutics (NASDAQ:BEAM) Upgraded by Zacks Investment Research to Hold

Beam Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Beam Therapeutics Upgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Beam Therapeutics (NASDAQ:BEAM) Upgraded by Zacks Investment Research to Hold

How Have the Numbers Shaped Up for Beam Therapeutics (NASDAQ:BEAM)

Earnings results for Beam Therapeutics , Analyst Opinion on Beam Therapeutics , Earnings and Valuation of (NASDAQ:BEAM), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More How Have the Numbers Shaped Up for Beam Therapeutics (NASDAQ:BEAM)

Factors Likely to Have Influenced Earnings Results Beam Therapeutics (NASDAQ:BEAM)

Earnings results for Beam Therapeutics , Analyst Opinion on Beam Therapeutics , Earnings and Valuation of (NASDAQ:BEAM), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Factors Likely to Have Influenced Earnings Results Beam Therapeutics (NASDAQ:BEAM)